Logo

Samsung Bioepis' Aybintio (SB8- biosimilar- bevacizumab) Receives the EC's Approval for Launch in EU

Share this

Samsung Bioepis' Aybintio (SB8- biosimilar- bevacizumab) Receives the EC's Approval for Launch in EU

Shots:

  • The EMA’s CHMP positive opinion was provided in June and is the fifth product which received the EU approval for autoimmune diseases and tumor diseases
  • The P-III study results of Abincio which involves 763 patients non-small cell lung cancer (NSCLC) patients and demonstrated the risk ratio of ORR vs original product- also presented at ESMO 2019
  •  Aybintio is a mAb targeted for metastatic carcinoma of the colon or rectum- metastatic breast cancer- non–small cell lung cancer- advanced or metastatic renal cell cancer- epithelial ovarian- fallopian tube and primary peritoneal cancer- and cervical cancer. In Nov 2019 the approval review of BLA is submitted to the US FDA and is also accepted

Ref: Samsung Bioepsis | Image: Samsung Bioepis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions